Trials / Active Not Recruiting
Active Not RecruitingNCT06023199
Assessing Physical Function in Sickle Cell Patients Taking Voxelotor
Assessing Functional Capacity in Sickle Cell Patients Receiving Voxelotor
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Inova Health Care Services · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Voxelotor is a novel hemoglobin polymerization inhibitor which has been demonstrated to reduce hemolysis and improve hemoglobin levels. There have been numerous studies examining the clinical impact of voxelotor in sickle cell disease (SCD) patients, but there are few published reports on the effects of treatment on physical function in patients with SCD. The hypothesis to be tested is that anemic SCD patients will have improvements in performance after 6 months of voxelotor treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Voxelotor | Voxelotor is administered orally at a dose of 1500mg daily. |
Timeline
- Start date
- 2023-10-23
- Primary completion
- 2025-09-17
- Completion
- 2026-06-15
- First posted
- 2023-09-05
- Last updated
- 2026-02-02
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06023199. Inclusion in this directory is not an endorsement.